NS-018

DRUG2 trials

Sponsors

NS Pharma, Inc.

Conditions

Post-Essential Thrombocythemia MyelofibrosisPost-Polycythemia Vera MyelofibrosisPost-essential Thrombocythemia MyelofibrosisPost-polycythemia Vera MyelofibrosisPrimary Myelofibrosis

Phase 1

Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF

CompletedNCT01423851

NS Pharma, Inc.Post-Essential Thrombocythemia Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Primary Myelofibrosis

Start: 2011-06-30End: 2020-04-22Updated: 2022-03-09

Phase 2

Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis

TerminatedNCT04854096

NS Pharma, Inc.Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Primary Myelofibrosis

Start: 2023-01-31End: 2024-05-16Updated: 2025-05-23

Related Papers

PB2232: A RANDOMIZED, CONTROLLED CLINICAL TRIAL (PHASE 2B) OF NS-018 VERSUS BEST AVAILABLE THERAPY IN SUBJECTS WITH PRIMARY OR SECONDARY MYELOFIBROSIS WITH SEVERE THROMBOCYTOPENIA

HemaSphere2023-08-01